20:21 , Aug 9, 2019 |  BioCentury  |  Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
11:00 , Aug 8, 2019 |  BC Extra  |  Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
12:40 , Apr 3, 2019 |  BC Extra  |  Company News

Editas, BlueRock to combine technologies for engineered cell medicines

Gene editing company Editas and cell therapy play BlueRock are collaborating to develop engineered, allogeneic cell medicines to treat neurologic, cardiologic, and immunologic disorders and cancer. Under a deal announced Wednesday, the companies will combine...
23:09 , Mar 29, 2019 |  BC Extra  |  Company News

Management tracks: Insmed, AACR, BlueRock

Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc. (NASDAQ:INSM) will begin to search for a successor. It also promoted John Goll to...
00:53 , Feb 1, 2019 |  BC Innovations  |  Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
00:01 , Nov 30, 2018 |  BC Extra  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
21:14 , Oct 3, 2018 |  BC Extra  |  Company News

Management tracks: ARM, Rewind, Exscientia

The Alliance for Regenerative Medicine, an advocacy organization for regenerative medicines including cell and gene therapies, appointed Matthew Patterson as chairman for 2019. The group also named Emile Nuwaysir as vice chairman, Amy Butler as...